PubMed Health⌕ Search

Biomedical subjects

J Owerbach

Publications and source records attributed to J Owerbach.

4 recordsLinked to original sources
PubMed1982

Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.

The pharmacokinetics and protein binding of sulfapyridine (SP) and its major metabolite, acetylsulfapyridine (ACSP) were examined in 17 prepubertal children and 4 postpubertal adolescents receiving sulfasalazine (SASP) for treatment of inflammatory bowel disease (IBD). Five patients were studied in both active disease and remission. Comparisons were made with a group of 24 outpatients (9-62 years) with IBD controlled on SASP and in remission. Acetylator phenotype was calculated from plasma metabolite ratios. Slow acetylators had increased plasma concentrations of SP and ACSP + SP (P less than 0.05). Apparent SP clearance (clearance/availability) was increased in active disease (P less than 0.05) and AUCSP + ACSP and AUCSP were decreased (P less than 0.05). There were no age-related alterations in apparent SP clearance. Side effects were frequent but were unrelated to SASP dose, SP concentrations, or acetylator phenotype. Disease activity did not significantly alter the serum protein binding of SP or ACSP. The decreased SP and ACSP concentrations seen in active disease may be due to a combination of disease related alterations in either cleavage of SASP or absorption and clearance of SP.

Acetylation↗
PubMed1981

Pharmacist selection of allergy medication based on patient response to trial regimens.

A trial medication package program was developed by an HMO for patients with allergic rhinitis, "hayfever," and related allergies. The use, patient evaluation, and cost savings of the program are reported. Physicians, nurse clinicians, and physician assistants refer patients into the allergy program for consultation with pharmacists. The pharmacists administering the program conduct a medication history, discuss the appropriate use of the medication in the trial package, and instruct the patient to call at the end of the trial for evaluation of the program, when two 30-dosage-unit refills for the most effective medication are available to the patient. The trial package consists of three sustained release antihistamine-decongestant preparations, a single-entity, short-acting antihistamine, and a single-entity, short-acting decongestant. The patient is charged $2 for the trial package program; the medication is provided by pharmaceutical companies at no cost. More than 300 patients were referred into the program in 1979. The program was evaluated as 'excellent-good' by 88% of 100 patients. The average savings were $3 per patient.

Costs and Cost Analysis↗
PubMed1978

High-performance liquid chromatographic assay of sulfapyridine and acetylsulfapyridine in biological fluids.

A high-pressure liquid chromatographic method for the sensitive, rapid, and specific determination of sulfapyridine and its N-acetyl derivative in plasma and saliva was developed. A cyano-bonded, reversed-phase, high efficiency column was used. The system detected these sulfonamides in serum to 0.25 mg/liter and within only 6 min. Sulfapyridine was separated from its acetyl derivative with little interference from other drugs. The assay reproducibility was within 3%. The assay was highly useful for routine monitoring of patients receiving sulfasalazine for inflammatory bowel disease.

Acetylation↗